| Patient | Isaac Newton |
|---|---|
| Date of birth | 1643-01-04 |
| Identifiers | MRN HR-EN011-SYN-TD; SSN (made up) 000-11-6840 |
| Document date | 2026-11-01 |
| Author | Rupert Okonkwo-Fairbanks, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Primary care visit for a year of poor sleep and appetite, two weeks of near-sleeplessness, and suspicious thoughts about friends, in a researcher who heats mercury and other metals. Concerns: He has barely slept for two weeks, eats little, and feels he has lost his former steadiness of mind; He wrote angry letters to friends he now thinks he wronged, and wants to make amends; He asks whether the metals in his laboratory have poisoned him. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Sertraline 50 mg oral tablet, one tablet by mouth each morning | One tablet by mouth each morning | Oral route | 1693-10-08 | active | S |
| Acetaminophen 500 mg oral tablet, one or two tablets by mouth every 6 hours as needed for aches or fever, no more than 3 g a day | One or two tablets every 6 hours as needed; no more than six tablets a day | Oral route | 1693-10-15 to 1693-10-22 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 1687-06-15 | Tdap vaccine | completed | S |
| 1686-03-04 | Hepatitis B vaccine, two-dose adult series completed | completed | S |
| 1693-10-22 | Influenza vaccine, 1693-1694 season | completed | S |
| 1693-10-22 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 1693-10-22 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| Autumn 1692 (Julian) | Loss of appetite and want of sleep from the previous autumn, continuing for nearly a year, by his biographer's account | D (CLM-0004) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| father | Died before the patient was born; cause not recorded in the cited source | D (CLM-0001) |
| Concern | Status | Evidence |
|---|---|---|
| He has barely slept for two weeks, eats little, and feels he has lost his former steadiness of mind | active | S |
| He wrote angry letters to friends he now thinks he wronged, and wants to make amends | active | S |
| He asks whether the metals in his laboratory have poisoned him | active | S |
Most recent measures: Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 14 on 1693-10-29; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 7 on 1693-10-29; Total score [MoCA] 27 on 1693-09-28; Hemoglobin [Mass/volume] in Blood 14.6 on 1693-09-28; MCV [Entitic mean volume] in Red Blood Cells by Automated count 91 on 1693-09-28; Leukocytes [#/volume] in Blood by Automated count 6.1 on 1693-09-28; Platelets [#/volume] in Blood by Automated count 242 on 1693-09-28; Sodium [Moles/volume] in Serum or Plasma 140 on 1693-09-28; Potassium [Moles/volume] in Serum or Plasma 4.3 on 1693-09-28; Urea nitrogen [Mass/volume] in Serum or Plasma 15 on 1693-09-28; Creatinine [Mass/volume] in Serum or Plasma 0.92 on 1693-09-28; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1688)/1.73 sq M 101 on 1693-09-28; Glucose [Mass/volume] in Serum or Plasma 88 on 1693-09-28; Calcium [Mass/volume] in Serum or Plasma 9.5 on 1693-09-28; Albumin [Mass/volume] in Serum or Plasma 4.2 on 1693-09-28; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 on 1693-09-28; Thyrotropin [Units/volume] in Serum or Plasma 1.9 on 1693-09-28; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 455 on 1693-09-28; Albumin/Creatinine [Mass Ratio] in Urine 9 on 1693-09-28; Mercury [Mass/volume] in Blood 3.1 on 1693-10-29; Lead [Mass/volume] in Blood 2.4 on 1693-09-28; Mercury [Mass/volume] in 24 hour Urine 31 on 1693-10-29; Mercury/Creatinine [Mass Ratio] in 24 hour Urine 27 on 1693-10-29; Cholesterol [Mass/volume] in Serum or Plasma 176 on 1693-10-22; Cholesterol in HDL [Mass/volume] in Serum or Plasma 61 on 1693-10-22; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 98 on 1693-10-22; Triglyceride [Mass/volume] in Serum or Plasma 86 on 1693-10-22 [S]
Strengths and supports: engagement in care [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| A year of poor sleep and poor appetite with 4 kg weight loss, two weeks of near-total sleeplessness, low spirits, and suspicious thoughts that colleagues and friends were plotting against him, now partly doubted; under evaluation for depression, a toxic cause, and other medical causes | resolved | confirmed | R45.89 | S — Synthetic presenting concern echoing the poor sleep, poor appetite, distress, and retracted suspicions documented in his letters of September 1693; superseded by the diagnoses at the second visit. |
| Occupational exposure to elemental and inorganic mercury, with lesser exposure to lead, antimony, and arsenic compounds, from heating metals in an unventilated private laboratory | active | confirmed | Z57.5 | S — Synthetic modern exposure echoing his documented chemical and alchemical work with metals, including mercury; no level of historical exposure is asserted. |
| Major depressive disorder, single episode, severe, without psychotic features (PHQ-9 20 at intake): a year of poor sleep and appetite with weight loss, low mood, poor concentration, and suspicious ideas held with partial insight; medical causes excluded; the contribution of low-level mercury exposure is uncertain | active | confirmed | F32.2 | S — Synthetic modern diagnosis. His sleeplessness, poor appetite, distress, and melancholy in 1693 are documented (D); calling them major depression is a modern reading, and mercury poisoning and other explanations proposed later are disputed (R). |
| Chronic insomnia comorbid with depression: sleep onset and maintenance difficulty for a year, with two weeks of near-total sleeplessness before intake | active | confirmed | G47.00 | S — Synthetic diagnosis echoing his documented sleeplessness. |
| Raised urine mercury from occupational exposure (24-hour urine 46 ug/L, 41 ug/g creatinine; blood 9.4 ug/L) without tremor, gingivitis, erethism, neuropathy, or kidney injury; below the levels linked to overt toxicity | active | confirmed | R82.6 | S — Synthetic result echoing his documented work with mercury; it does not assert that he was poisoned (see CLM-0011, R, disputed). |
| Acute viral upper respiratory infection (common cold) with a low-grade fever, sore throat, and cough, a week after starting sertraline; resolved | resolved | confirmed | J06.9 | S — Synthetic intercurrent illness at an unscheduled visit; it echoes, without asserting, his documented mention of a distemper that was epidemical that summer (CLM-0008). |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1693-09-28 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 20 | {score} | S | ||
| 1693-09-28 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 11 | {score} | S | ||
| 1693-09-28 | Total score [MoCA] | 27 | {score} | S | ||
| 1693-09-28 | Hemoglobin [Mass/volume] in Blood | 14.6 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 1693-09-28 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 91 | fL | 80-100 fL | Normal | S |
| 1693-09-28 | Leukocytes [#/volume] in Blood by Automated count | 6.1 | 10*3/uL | 3.4-9.6 10*3/uL | Normal | S |
| 1693-09-28 | Platelets [#/volume] in Blood by Automated count | 242 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1693-09-28 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 1693-09-28 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1693-09-28 | Urea nitrogen [Mass/volume] in Serum or Plasma | 15 | mg/dL | 8-24 mg/dL | Normal | S |
| 1693-09-28 | Creatinine [Mass/volume] in Serum or Plasma | 0.92 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1693-09-28 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1688)/1.73 sq M | 101 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1693-09-28 | Glucose [Mass/volume] in Serum or Plasma | 88 | mg/dL | 70-99 mg/dL | Normal | S |
| 1693-09-28 | Calcium [Mass/volume] in Serum or Plasma | 9.5 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 1693-09-28 | Albumin [Mass/volume] in Serum or Plasma | 4.2 | g/dL | 3.5-5 g/dL | Normal | S |
| 1693-09-28 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 7-55 U/L | Normal | S |
| 1693-09-28 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.4-4 mIU/L | Normal | S |
| 1693-09-28 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 455 | pg/mL | 232-1245 pg/mL | Normal | S |
| 1693-09-28 | Albumin/Creatinine [Mass Ratio] in Urine | 9 | mg/g{creat} | <=30 mg/g{creat} | Normal | S |
| 1693-09-28 | Mercury [Mass/volume] in Blood | 9.4 | ug/L | 95th percentile of US adults below 5 ug/L (ATSDR); 50 ug/L or more is the threshold for symptoms of toxicity | High | S |
| 1693-09-28 | Lead [Mass/volume] in Blood | 2.4 | ug/dL | Below 3.5 ug/dL (CDC blood lead reference value) | Normal | S |
| 1693-09-28 | Mercury [Mass/volume] in 24 hour Urine | 46 | ug/L | Background below 2 ug/L (95th percentile of adults); below 20 ug/L not associated with effects (ATSDR) | High | S |
| 1693-09-28 | Mercury/Creatinine [Mass Ratio] in 24 hour Urine | 41 | ug/g{creat} | Occupational biological exposure index 20 ug/g creatinine | High | S |
| 1693-10-08 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 19 | {score} | S | ||
| 1693-10-22 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 16 | {score} | S | ||
| 1693-10-22 | Cholesterol [Mass/volume] in Serum or Plasma | 176 | mg/dL | <=199 mg/dL | Normal | S |
| 1693-10-22 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 61 | mg/dL | >=40 mg/dL | Normal | S |
| 1693-10-22 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 98 | mg/dL | <=129 mg/dL | Normal | S |
| 1693-10-22 | Triglyceride [Mass/volume] in Serum or Plasma | 86 | mg/dL | <=149 mg/dL | Normal | S |
| 1693-10-29 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 14 | {score} | S | ||
| 1693-10-29 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 7 | {score} | S | ||
| 1693-10-29 | Mercury [Mass/volume] in Blood | 3.1 | ug/L | 95th percentile of US adults below 5 ug/L (ATSDR); 50 ug/L or more is the threshold for symptoms of toxicity | Normal | S |
| 1693-10-29 | Mercury [Mass/volume] in 24 hour Urine | 31 | ug/L | Background below 2 ug/L (95th percentile of adults); below 20 ug/L not associated with effects (ATSDR) | High | S |
| 1693-10-29 | Mercury/Creatinine [Mass Ratio] in 24 hour Urine | 27 | ug/g{creat} | Occupational biological exposure index 20 ug/g creatinine | High | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1693-09-28 | Body height | 170 | cm | S |
| 1693-09-28 | Body weight | 64 | kg | S |
| 1693-09-28 | Body mass index (BMI) [Ratio] | 22.1 | kg/m2 | S |
| 1693-09-28 | Systolic blood pressure | 124 | mm[Hg] | S |
| 1693-09-28 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1693-09-28 | Heart rate | 84 | /min | S |
| 1693-09-28 | Respiratory rate | 14 | /min | S |
| 1693-09-28 | Body temperature | 36.7 | Cel | S |
| 1693-09-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1693-10-08 | Body height | 170 | cm | S |
| 1693-10-08 | Body weight | 63.8 | kg | S |
| 1693-10-08 | Body mass index (BMI) [Ratio] | 22.1 | kg/m2 | S |
| 1693-10-08 | Systolic blood pressure | 122 | mm[Hg] | S |
| 1693-10-08 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1693-10-08 | Heart rate | 80 | /min | S |
| 1693-10-08 | Respiratory rate | 14 | /min | S |
| 1693-10-08 | Body temperature | 36.6 | Cel | S |
| 1693-10-08 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1693-10-15 | Body height | 170 | cm | S |
| 1693-10-15 | Body weight | 63.9 | kg | S |
| 1693-10-15 | Body mass index (BMI) [Ratio] | 22.1 | kg/m2 | S |
| 1693-10-15 | Systolic blood pressure | 120 | mm[Hg] | S |
| 1693-10-15 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1693-10-15 | Heart rate | 90 | /min | S |
| 1693-10-15 | Respiratory rate | 16 | /min | S |
| 1693-10-15 | Body temperature | 37.8 | Cel | S |
| 1693-10-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1693-10-22 | Body height | 170 | cm | S |
| 1693-10-22 | Body weight | 64.3 | kg | S |
| 1693-10-22 | Body mass index (BMI) [Ratio] | 22.2 | kg/m2 | S |
| 1693-10-22 | Systolic blood pressure | 120 | mm[Hg] | S |
| 1693-10-22 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1693-10-22 | Heart rate | 76 | /min | S |
| 1693-10-22 | Respiratory rate | 14 | /min | S |
| 1693-10-22 | Body temperature | 36.6 | Cel | S |
| 1693-10-22 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1693-10-29 | Body height | 170 | cm | S |
| 1693-10-29 | Body weight | 64.8 | kg | S |
| 1693-10-29 | Body mass index (BMI) [Ratio] | 22.4 | kg/m2 | S |
| 1693-10-29 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1693-10-29 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1693-10-29 | Heart rate | 72 | /min | S |
| 1693-10-29 | Respiratory rate | 14 | /min | S |
| 1693-10-29 | Body temperature | 36.6 | Cel | S |
| 1693-10-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 1693-09-28 | Primary care visit for a year of poor sleep and appetite, two weeks of near-sleeplessness, and suspicious thoughts about friends, in a researcher who heats mercury and other metals | finished | S |
| 1693-10-08 | Ten-day review of metal and laboratory results, diagnosis, start of treatment, and occupational and environmental medicine consultation | finished | S |
| 1693-10-29 | Three-week depression and exposure follow-up with a repeat 24-hour urine mercury | finished | S |
| 1693-10-15 | Same-day sick visit for a cold one week after starting sertraline | finished | S |
| 1693-10-22 | Preventive health visit at 50 | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Workup for medical and toxic causes: blood count, metabolic panel, TSH, vitamin B12, MoCA, urine albumin-to-creatinine ratio and dipstick protein, blood mercury, 24-hour urine mercury with creatinine, and blood lead; examination for tremor, gingivitis, stomatitis, and neuropathy; no provoked (chelator-challenge) urine test and no broad metal screen | completed | GL-CMID-2026, GL-APA-DEP-2019, GL-MDD-2022, GL-ATSDR-HG-2018, GL-NIOSH-HG, GL-ACMT-2010, GL-ACMT-CHEL-2013 | S |
| Removal from exposure now: stop all heating of metals, close the laboratory, and do not sleep in the adjoining rooms until they are checked; the university environmental health and safety office to measure mercury vapor, decontaminate, and remove the mercury and arsenic compounds | completed | GL-ATSDR-HG-2018, GL-NIOSH-HG, GL-ACMT-2010, GL-ACMT-CHEL-2013 | S |
| Suicide and violence risk assessment with a safety plan: warning signs, coping steps, people to contact, the clinic number, and the 988 Suicide & Crisis Lifeline; toxic chemicals out of reach; safety reviewed at every visit | completed | GL-SUICIDE-2024, GL-CMID-2026 | S |
| Occupational and environmental medicine (medical toxicology) consultation on the meaning of the mercury results, chelation, the workplace hazard assessment, and a safe return to laboratory work | completed | GL-ATSDR-HG-2018, GL-NIOSH-HG, GL-ACMT-2010, GL-ACMT-CHEL-2013 | S |
| Sleep: cognitive behavioral therapy for insomnia (a fixed rising time, a sleep window, out of bed after 20 minutes awake, no dozing in the evening chair, no night work); no hypnotics or sedating antihistamines | completed | GL-ACP-INSOMNIA-2016 | S |
| Shared decision on depression treatment: sertraline 50 mg each morning with weekly cognitive behavioral therapy; PHQ-9 at every visit; an increase if the response is under 50 percent after six to eight weeks; continue for at least six to twelve months after remission | completed | GL-CMID-2026, GL-APA-DEP-2019, GL-MDD-2022, GL-DSM5TR-2022 | S |
| Collaborative care: the clinic's psychiatrist reviews his PHQ-9, safety, and medicine each week with the care manager, and sees him in person if psychotic features, suicidal thoughts, or thoughts of harming others appear, or if he does not respond | completed | GL-CMID-2026, GL-APA-DEP-2019, GL-MDD-2022 | S |
| Exposure follow-up: repeat 24-hour urine mercury and blood mercury four to six weeks after removal and again at three months; creatinine and urine albumin-to-creatinine ratio at three months; return to laboratory work only with a fume hood, a mercury spill kit, no food at the bench, and urine mercury below the biological exposure index | completed | GL-ATSDR-HG-2018, GL-NIOSH-HG, GL-ACMT-2010, GL-ACMT-CHEL-2013 | S |
| Nutrition: three regular meals a day, weight at every visit | completed | GL-CMID-2026, GL-APA-DEP-2019, GL-MDD-2022 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Toxic and other medical causes assessed by the second visit | 1693-10-08 | completed | Blood count, metabolic panel, TSH, vitamin B12, kidney tests, blood lead, and MoCA normal; blood and urine mercury raised from his work, below levels linked to overt toxicity | S |
| No further exposure to mercury and other metals until the laboratory is made safe | 1694-01-31 | active | Laboratory closed since intake; urine mercury falling | S |
| Response (PHQ-9 down by at least 50 percent) by eight to twelve weeks of treatment, then remission (PHQ-9 below 5) | 1693-12-31 | active | PHQ-9 14 after three weeks of sertraline, 30 percent below baseline | S |
| No suicidal thoughts and no thoughts of harming others | 1693-12-31 | active | None at any visit | S |
| At least six hours of sleep most nights without hypnotics | 1693-12-31 | active | About five and a half hours by the third chronic-care visit | S |
Structured synthetic safety assessment on 1693-09-28: current ideation absent, intent absent, plan absent. No suicidal ideation, intent, plan, or behavior (C-SSRS screen negative; PHQ-9 item 9 scored 0). No thoughts or intent of harming others; an angry remark about a friend is regretted, with no history of violence. Severe insomnia and depressive symptoms raise risk, so: outpatient care with a safety plan, the 988 Suicide & Crisis Lifeline and the clinic number, the laboratory closed today and its mercury and arsenic compounds to be removed by the university safety office, and review at every visit [S]